



STENTYS successfully completes €36 million capital increase

PARIS – November 13, 2012 – STENTYS (FR0010949404 – STNT), (the “Company”) announces the successful completion of its capital increase with preemptive rights launched on October 23, 2012.

The final gross proceeds of the transaction amount to €36,364,968 corresponding to the issuance of 3,030,414 new shares.

Total subscription orders for this capital increase amounted to approximately €47.6 million, i.e., a subscription rate of approximately 131.0%.

- 2,944,800 new shares were subscribed on an irreducible basis (“à titre irréductible”), representing approximately 97.2% of the new shares to be issued.
- Subscription orders subject to reduction (“à titre réductible”) amounted to 1,025,510 new shares and will, as a result, be satisfied only in part, i.e. for 85,614 new shares.

This transaction was launched following STENTYS’ announcement on October 22, 2012 of the Investigational Device Exemption (IDE) approval by the FDA, and aims at providing the Company with additional resources to finance:

- the APPOSITION V clinical study in the United States which, upon successful completion, will enable the Company to file for market approval of the STENTYS bare metal stent; the study is anticipated to start in the first quarter of 2013; and
- its commercial deployment, by increasing its direct sales force in Europe and recruiting a network of distributors in countries in which the Company already has market authorization for its products.

The Fonds Stratégique d’Investissement (« FSI ») participated in this capital increase to support STENTYS’ development, with the intention to become long-term shareholder of the group. Following the transaction, the FSI will hold 7.8% of STENTYS’ share capital and voting rights.

“The high subscription rate from current shareholders in this offering serves as validation for our strategy and we are grateful for the long-term support of investors, like FSI, Sofinnova and Omnes” said Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS. “We now have the means to execute our business plan to offer STENTYS Self-Apposing technology to all heart attack patients across Europe and the US”.

The settlement and delivery and the listing of the new shares on the regulated market of NYSE Euronext in Paris are expected to take place on November 15, 2012. The new shares will carry full dividend rights and will be traded on the same trading line as STENTYS’ existing shares under the same ISIN code FR0010949404.

Kempen & Co and Société Générale Corporate & Investment Banking are acting as Joint Lead Managers and Joint Bookrunners of the transaction.

Information available to the public

The prospectus, filed with the Autorité des marchés financiers (“AMF”) under number 12-508 dated October 22, 2012 consists of the registration document (*document de référence*) (the “Registration Document”) of STENTYS registered with the AMF on June 25, 2012 under number R.12-033, the update to the Registration Document (*actualisation du document de référence*) (the “2011 Registration Document Update”) of STENTYS filed with the AMF on October 22, 2012 under number D.12-0531-A01, a securities note (the “Securities Note”) and a summary of the prospectus (included in the securities note).

Copies of the prospectus filed with the AMF may be obtained free of charge from STENTYS’ administrative office (25, rue de Choiseul, 75002 Paris) and are also available on STENTYS’ website (www.stentys.com) and the AMF’s website (www.amf-france.org), and from the Joint Lead Managers and Joint Bookrunners.

STENTYS draws investors’ attention to the risk factors described in section 4 of the Registration Document as updated by the 2011 Registration Document Update, as well as in section 2 of the Securities Note.



About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low 30-day mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. **More information is available at www.stentys.com.**

STENTYS

Stanislas Piot
CFO
Tél. : +33 (0)1 44 53 99 42
investors@stentys.com

NewCap.

Axelle Vuillermet / Pierre Laurent
Tél. : +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN : FR0010949404 – Mnémonique : STNT

Disclaimer

This press release contains forward-looking statements including about the Company's business and prospects and the proposed offering of shares of the Company. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future and which may not be accurate. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with development and commercialization of the Company's products, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company's BMS, slower than expected rates of patient recruitment for clinical trials, including the APPOSITION V clinical trial, the outcome of the APPOSITION III and other clinical trials, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, changes in market conditions and the price of the Company's shares, success of the proposed offering, and other factors, including those described in the Section 4 of our 2011 Registration Document Update and Section 2 of the Securities Note as referred to herein.

No communication and no information in respect of this transaction or of STENTYS may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken in any jurisdiction (other than France) where such steps would be required. The issue, the subscription for or the purchase of STENTYS' preemptive rights and shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. STENTYS assumes no responsibility for any violation of any such restrictions by any person.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company in the United States or in any other jurisdiction. The preemptive rights and shares of STENTYS may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or exempt from registration. The preemptive rights and shares of STENTYS have not been and will not be registered under the U.S. Securities Act and STENTYS does not intend to make any public offer of its securities in the United States.

The distribution of this press release in certain countries may be subject to specific regulations. The persons in possession of this press release must inform themselves of any local restrictions and comply therewith.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, to the extent such Directive has been transposed in the relevant member State of the European Economic Area (the "Prospectus Directive").



With respect to the Member States of the European Economic Area which have implemented the Prospectus Directive (each a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State, other than France. As a result, the preemptive rights or shares of the Company may only be offered and will only be offered in any Relevant Member State other than France, (i) to any legal entity which is a qualified investor as defined under the Prospectus Directive; (ii) to fewer than 100, or, if the Relevant Member State has implemented the relevant provisions of Directive 2010/73/EU, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive) as permitted under the Prospectus Directive, subject to obtaining the prior consent of the Joint Lead Managers and Joint Bookrunners for any such offer; or (iii) in any other circumstances not requiring the Company to publish a prospectus as provided under Article 3(2) of the Prospectus Directive and/or regulations applicable in this Relevant Member State, provided that no such offer in (i) to (iii) shall result in a requirement for the Company to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expression an "offer to the public" in relation to the preemptive rights and the shares of the Company in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the preemptive rights or the shares of the Company to be offered so as to enable an investor to decide to purchase the preemptive rights or the shares of the Company, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State.

In the United Kingdom, this press release does not constitute an approved prospectus for the purpose of and as defined in section 85 of the Financial Services and Markets Act 2000 (as amended) (the "FSMA") and is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth bodies corporate, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons."